Cellular Biomedicine Group EBIT

Cellular Biomedicine Group (CBMG) currently reports a EBIT of $-55M as of September 2020. That compares with $-46M in the prior-year period — down 19.6% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Cellular Biomedicine Group's EBIT history and peer comparisons.

Cellular Biomedicine Group's EBIT decreased from $-46M to $-55M — a 19.6% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellular Biomedicine Group's EBIT of $-55M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Cellular Biomedicine Group reported $-55M in EBIT as of September 2020. That compares with $-46M in the prior-year period — down 19.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-55M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Cellular Biomedicine Group, and consider following CBMG for alerts when major investors trade the stock.